ASX Announcements

Investor presentation, 14 September 2022
Rett Syndrome New Drug Application accepted for Priority Review by FDA
S&P DJI Announces September 2022 Quarterly Rebalance
Half-year shareholder update
Half Yearly Report and Accounts
Investor presentation, 8 August 2022
Neuren commences Phase 2 trials of NNZ-2591 in PMS and PTHS
Quarterly Activities/Appendix 4C Cash Flow Report
Acadia submits Rett Syndrome New Drug Application to the FDA
Neuren commences Phase 2 trial of NNZ-2591 in Angelman syndrome